The relationship between expression of EGFR, MMP-9, and C-erbB-2 and survival time in resected non-small cell lung cancer

Seung Heon Lee, Jin Yong Jung, Kyoung Ju Lee, Seung Hyeun Lee, Se Joong Kim, Eun Sil Ha, Eun Joo Lee, Gyu Young Hur, Ki Hwan Jung, Hye Cheol Jung, Sung Yong Lee, Je Hyeong Kim, Sang Yeub Lee, Chol Shin, Jae Jeong Shim, Kwang Ho In, Kyung Ho Kang, Se Hwa Yoo, Chul Hwan Kim

Research output: Contribution to journalArticle

Abstract

Background: Non-small cell lung cancer (NSCLC) is a common cause of cancer-related death in North America and Korea, with an overall 5-year survival rate of between 4 and 14% The TNM staging system is the best prognostic index for operable NSCLC. However, epidermal growth factor receptor (EGFR), matrix metalloproteinase-9(MMP-9), and C-erbB-2 have all been implicated in the pathogenesis of NSCLC and might provide prognostic information. Methods: Immunohistochemical staining of 81 specimens from a resected primary non-small cell lung cancer was evaluated in order to determine the role of the biological markers on NSCLC. Immunohistochemical staining for EGFR, MMP-9, and C-erbB-2 was performed on paraffin-embedded tissue sections to observe the expression pattern according to the pathologic type and surgical staging. The correlations between the expression of each biological marker and the survival time was determined. Results: When positive immunohistochemical staining was defined as the extent area>20%(more than Grade 2), the positive rates for EGFR, MMP-9, and C-erbB-2 staining were 71.6%, 44.3%, and 24.1% of the 81 patients, respectively. The positive rates of EGFR and MMP-9 stain for NSCLC according to the surgical stages I, II, and IIIa were 75.0% and 41.7%, 66.7% and 47.6%, and 76.9% and 46.2%, respectively. The median survival time of the EGFR(-) group, 71.8 months, was significantly longer than that of the EGFR(+) group, 33.5 months.(p=0.018, Kaplan-Meier Method, log-rank test). The MMP-9(+) group had a shorter median survival time than the MMP-9(-) group, 35.0 and 65.3 months, respectively (p=0.2). The co-expression of EGFR and MMP-9 was associated with a worse prognosis with a median survival time of 26.9 months , when compared with the 77 months for both negative-expression groups (p=0.0023). There were no significant differences between the C-erbB-2(+) and C-erbB-2 (-) groups. Conclusion: In NSCLC, the expression of EGFR might be a prognostic factor, and the co expression of EGFR and MMP-9 was found to be associated with a poor prognosis. However, C-erbB-2 expression had no prognostic significance.

Original languageEnglish
Pages (from-to)286-297
Number of pages12
JournalTuberculosis and Respiratory Diseases
Volume59
Issue number3
Publication statusPublished - 2005 Sep 1

Fingerprint

Matrix Metalloproteinase 9
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Survival
Staining and Labeling
Democratic People's Republic of Korea
Biomarkers
Neoplasm Staging
North America
Paraffin
Coloring Agents
Survival Rate

Keywords

  • C-erbB-2
  • EGFR
  • MMP-9
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The relationship between expression of EGFR, MMP-9, and C-erbB-2 and survival time in resected non-small cell lung cancer. / Lee, Seung Heon; Jung, Jin Yong; Lee, Kyoung Ju; Lee, Seung Hyeun; Kim, Se Joong; Ha, Eun Sil; Lee, Eun Joo; Hur, Gyu Young; Jung, Ki Hwan; Jung, Hye Cheol; Lee, Sung Yong; Kim, Je Hyeong; Lee, Sang Yeub; Shin, Chol; Shim, Jae Jeong; In, Kwang Ho; Kang, Kyung Ho; Yoo, Se Hwa; Kim, Chul Hwan.

In: Tuberculosis and Respiratory Diseases, Vol. 59, No. 3, 01.09.2005, p. 286-297.

Research output: Contribution to journalArticle

@article{1cb3f41510be449888a1245d0e1f0639,
title = "The relationship between expression of EGFR, MMP-9, and C-erbB-2 and survival time in resected non-small cell lung cancer",
abstract = "Background: Non-small cell lung cancer (NSCLC) is a common cause of cancer-related death in North America and Korea, with an overall 5-year survival rate of between 4 and 14{\%} The TNM staging system is the best prognostic index for operable NSCLC. However, epidermal growth factor receptor (EGFR), matrix metalloproteinase-9(MMP-9), and C-erbB-2 have all been implicated in the pathogenesis of NSCLC and might provide prognostic information. Methods: Immunohistochemical staining of 81 specimens from a resected primary non-small cell lung cancer was evaluated in order to determine the role of the biological markers on NSCLC. Immunohistochemical staining for EGFR, MMP-9, and C-erbB-2 was performed on paraffin-embedded tissue sections to observe the expression pattern according to the pathologic type and surgical staging. The correlations between the expression of each biological marker and the survival time was determined. Results: When positive immunohistochemical staining was defined as the extent area>20{\%}(more than Grade 2), the positive rates for EGFR, MMP-9, and C-erbB-2 staining were 71.6{\%}, 44.3{\%}, and 24.1{\%} of the 81 patients, respectively. The positive rates of EGFR and MMP-9 stain for NSCLC according to the surgical stages I, II, and IIIa were 75.0{\%} and 41.7{\%}, 66.7{\%} and 47.6{\%}, and 76.9{\%} and 46.2{\%}, respectively. The median survival time of the EGFR(-) group, 71.8 months, was significantly longer than that of the EGFR(+) group, 33.5 months.(p=0.018, Kaplan-Meier Method, log-rank test). The MMP-9(+) group had a shorter median survival time than the MMP-9(-) group, 35.0 and 65.3 months, respectively (p=0.2). The co-expression of EGFR and MMP-9 was associated with a worse prognosis with a median survival time of 26.9 months , when compared with the 77 months for both negative-expression groups (p=0.0023). There were no significant differences between the C-erbB-2(+) and C-erbB-2 (-) groups. Conclusion: In NSCLC, the expression of EGFR might be a prognostic factor, and the co expression of EGFR and MMP-9 was found to be associated with a poor prognosis. However, C-erbB-2 expression had no prognostic significance.",
keywords = "C-erbB-2, EGFR, MMP-9, Non-small cell lung cancer",
author = "Lee, {Seung Heon} and Jung, {Jin Yong} and Lee, {Kyoung Ju} and Lee, {Seung Hyeun} and Kim, {Se Joong} and Ha, {Eun Sil} and Lee, {Eun Joo} and Hur, {Gyu Young} and Jung, {Ki Hwan} and Jung, {Hye Cheol} and Lee, {Sung Yong} and Kim, {Je Hyeong} and Lee, {Sang Yeub} and Chol Shin and Shim, {Jae Jeong} and In, {Kwang Ho} and Kang, {Kyung Ho} and Yoo, {Se Hwa} and Kim, {Chul Hwan}",
year = "2005",
month = "9",
day = "1",
language = "English",
volume = "59",
pages = "286--297",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "3",

}

TY - JOUR

T1 - The relationship between expression of EGFR, MMP-9, and C-erbB-2 and survival time in resected non-small cell lung cancer

AU - Lee, Seung Heon

AU - Jung, Jin Yong

AU - Lee, Kyoung Ju

AU - Lee, Seung Hyeun

AU - Kim, Se Joong

AU - Ha, Eun Sil

AU - Lee, Eun Joo

AU - Hur, Gyu Young

AU - Jung, Ki Hwan

AU - Jung, Hye Cheol

AU - Lee, Sung Yong

AU - Kim, Je Hyeong

AU - Lee, Sang Yeub

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - In, Kwang Ho

AU - Kang, Kyung Ho

AU - Yoo, Se Hwa

AU - Kim, Chul Hwan

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: Non-small cell lung cancer (NSCLC) is a common cause of cancer-related death in North America and Korea, with an overall 5-year survival rate of between 4 and 14% The TNM staging system is the best prognostic index for operable NSCLC. However, epidermal growth factor receptor (EGFR), matrix metalloproteinase-9(MMP-9), and C-erbB-2 have all been implicated in the pathogenesis of NSCLC and might provide prognostic information. Methods: Immunohistochemical staining of 81 specimens from a resected primary non-small cell lung cancer was evaluated in order to determine the role of the biological markers on NSCLC. Immunohistochemical staining for EGFR, MMP-9, and C-erbB-2 was performed on paraffin-embedded tissue sections to observe the expression pattern according to the pathologic type and surgical staging. The correlations between the expression of each biological marker and the survival time was determined. Results: When positive immunohistochemical staining was defined as the extent area>20%(more than Grade 2), the positive rates for EGFR, MMP-9, and C-erbB-2 staining were 71.6%, 44.3%, and 24.1% of the 81 patients, respectively. The positive rates of EGFR and MMP-9 stain for NSCLC according to the surgical stages I, II, and IIIa were 75.0% and 41.7%, 66.7% and 47.6%, and 76.9% and 46.2%, respectively. The median survival time of the EGFR(-) group, 71.8 months, was significantly longer than that of the EGFR(+) group, 33.5 months.(p=0.018, Kaplan-Meier Method, log-rank test). The MMP-9(+) group had a shorter median survival time than the MMP-9(-) group, 35.0 and 65.3 months, respectively (p=0.2). The co-expression of EGFR and MMP-9 was associated with a worse prognosis with a median survival time of 26.9 months , when compared with the 77 months for both negative-expression groups (p=0.0023). There were no significant differences between the C-erbB-2(+) and C-erbB-2 (-) groups. Conclusion: In NSCLC, the expression of EGFR might be a prognostic factor, and the co expression of EGFR and MMP-9 was found to be associated with a poor prognosis. However, C-erbB-2 expression had no prognostic significance.

AB - Background: Non-small cell lung cancer (NSCLC) is a common cause of cancer-related death in North America and Korea, with an overall 5-year survival rate of between 4 and 14% The TNM staging system is the best prognostic index for operable NSCLC. However, epidermal growth factor receptor (EGFR), matrix metalloproteinase-9(MMP-9), and C-erbB-2 have all been implicated in the pathogenesis of NSCLC and might provide prognostic information. Methods: Immunohistochemical staining of 81 specimens from a resected primary non-small cell lung cancer was evaluated in order to determine the role of the biological markers on NSCLC. Immunohistochemical staining for EGFR, MMP-9, and C-erbB-2 was performed on paraffin-embedded tissue sections to observe the expression pattern according to the pathologic type and surgical staging. The correlations between the expression of each biological marker and the survival time was determined. Results: When positive immunohistochemical staining was defined as the extent area>20%(more than Grade 2), the positive rates for EGFR, MMP-9, and C-erbB-2 staining were 71.6%, 44.3%, and 24.1% of the 81 patients, respectively. The positive rates of EGFR and MMP-9 stain for NSCLC according to the surgical stages I, II, and IIIa were 75.0% and 41.7%, 66.7% and 47.6%, and 76.9% and 46.2%, respectively. The median survival time of the EGFR(-) group, 71.8 months, was significantly longer than that of the EGFR(+) group, 33.5 months.(p=0.018, Kaplan-Meier Method, log-rank test). The MMP-9(+) group had a shorter median survival time than the MMP-9(-) group, 35.0 and 65.3 months, respectively (p=0.2). The co-expression of EGFR and MMP-9 was associated with a worse prognosis with a median survival time of 26.9 months , when compared with the 77 months for both negative-expression groups (p=0.0023). There were no significant differences between the C-erbB-2(+) and C-erbB-2 (-) groups. Conclusion: In NSCLC, the expression of EGFR might be a prognostic factor, and the co expression of EGFR and MMP-9 was found to be associated with a poor prognosis. However, C-erbB-2 expression had no prognostic significance.

KW - C-erbB-2

KW - EGFR

KW - MMP-9

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=26944480423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944480423&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:26944480423

VL - 59

SP - 286

EP - 297

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 3

ER -